UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 17, 2016
Editas Medicine, Inc.
(Exact Name of Registrant as Specified in its Charter)
| | | | |
Delaware | | 001‑37687 | | 46‑4097528 |
(State or Other Jurisdiction
of Incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
| | |
11 Hurley Street
Cambridge, Massachusetts | | 02141 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (617) 401‑9000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)
☐ Pre-commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b))
☐ Pre-commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))
Explanatory Note
Editas Medicine, Inc. (the “Company”) is filing this Current Report on Form 8-K solely for the purpose of filing as exhibits certain agreements that the Company has entered into for which the Company is requesting confidential treatment as to certain portions. The Company previously reported its entry into the agreements attached as Exhibits 99.1, 99.2, and 99.3 hereto in a Current Report on Form 8-K filed on December 21, 2016. The Company did not previously report its entry into the Second Amendment to Exclusive Patent License Agreement attached as Exhibit 99.4 hereto in a Current Report on Form 8-K as a result of the Company’s determination that such amendment was immaterial to the Company, notwithstanding the materiality to the Company of the agreement to which the amendment related.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| | |
Exhibit
No. | | Description |
99.1† | | Cpf1 License Agreement, by and between the Company and the Broad Institute, Inc., dated December 16, 2016 |
99.2† | | Amended and Restated Cas9‑I License Agreement, by and between the Company, President and Fellows of Harvard College, and the Broad Institute Inc., dated December 16, 2016 |
99.3† | | Cas9‑II License Agreement, by and between the Company and the Broad Institute, Inc., dated December 16, 2016 |
99.4† | | Second Amendment to Exclusive Patent License Agreement, by and between the Company and The General Hospital Corporation d/b/a Massachusetts General Hospital, dated November 17, 2016 |
| | |
† Confidential treatment requested as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| EDITAS MEDICINE, INC. |
| | |
Date: January 23, 2017 | By: | /s/ Andrew A. F. Hack |
| | Andrew A. F. Hack |
| | Chief Financial Officer |
EXHIBIT INDEX
| | |
Exhibit
No. | | Description |
99.1† | | Cpf1 License Agreement, by and between the Company and the Broad Institute, Inc., dated December 16, 2016 |
99.2† | | Amended and Restated Cas9‑I License Agreement, by and between the Company, President and Fellows of Harvard College, and the Broad Institute Inc., dated December 16, 2016 |
99.3† | | Cas9‑II License Agreement, by and between the Company and the Broad Institute, Inc., dated December 16, 2016 |
99.4† | | Second Amendment to Exclusive Patent License Agreement, by and between the Company and The General Hospital Corporation d/b/a Massachusetts General Hospital, dated November 17, 2016 |
| | |
| | |
† Confidential treatment requested as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.
